CELC Celcuity

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held on August 7-8, 2023.

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at . The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Further information about Celcuity can be found at . Follow us on  and . 

Contacts:

Celcuity Inc.

Brian Sullivan, Vicky Hahne, (763) 392-0123

ICR Westwicke

Robert Uhl,   

(619) 228-5886



EN
31/07/2023

Underlying

CELCCelcuity

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celcuity

 PRESS RELEASE
Free
CELC CELCUITY

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Fin...

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026, for gedatolisib in HR+/HER2-/PIK3CA wild-type (“WT”) advanced breast cancer (“ABC”)Results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 study of gedatolisib regimens in HR+/HER2- ABC published in Journal of Clinical OncologyTopline results from the PIK3CA mutant cohort of the Phase 3...

March 25, 2026 1 EN
 PRESS RELEASE
Free
CELC CELCUITY

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financ...

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Con...

March 18, 2026 1 EN
 PRESS RELEASE
Free
CELC CELCUITY

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort...

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus fulvestrant by 76% and 67%, respectively MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for...

March 9, 2026 1 EN
 PRESS RELEASE
Free
CELC CELCUITY

Celcuity To Participate in Upcoming Investor Conferences

Celcuity To Participate in Upcoming Investor Conferences MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen 46th Annual Healthcare Conference at 10:30 a.m. ET on Wednesday, March 4, 2026. A live webcast will be available using this weblink: A fires...

February 25, 2026 1 EN
 PRESS RELEASE
Free
CELC CELCUITY

Celcuity Appoints Charles Romp to its Board of Directors

Celcuity Appoints Charles Romp to its Board of Directors MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams and commercial organizations in the oncology setting. “Chip brings a wealth of oncology-related commercial expertise to our Board,” said Brian Sullivan, Ch...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch